Source comparison
Receptor Mechanism: Ghrelin Mimicry vs GHRH Pathway Activation
MK-677 binds to the ghrelin receptor (GHSR-1a) with sub-nanomolar affinity, mimicking the endogenous hunger hormone ghrelin. This receptor coupling triggers intracellular calcium release in somatotroph cells of the anterior pituitary, stimulating growth hormon
This comparison does not assign a generated winner or score.
- MK-677 binds to the ghrelin receptor (GHSR-1a) with sub-nanomolar affinity, mimicking the endogenous hunger hormone ghrelin. This receptor coupling triggers intracellular calcium release in somatotroph cells of the anterior pituitary, stimulating growth hormone secretion independent of growth hormone-releasing hormone (GHRH). The result: sustained GH elevation lasting 24+ hours from a single oral dose, with IGF-1 levels peaking 4–6 hours post-administration and remaining elevated throughout the day.
- GHRP-2, GHRP-6, and Ipamorelin operate through the growth hormone secretagogue receptor (GHS-R), which overlaps partially with ghrelin receptor signaling but requires synergy with endogenous GHRH for maximal effect. These peptides produce acute GH spikes 30–90 minutes post-injection, with serum levels returning to baseline within 3–4 hours. The pulsatile nature mirrors physiological GH secretion patterns. Useful in studies examining circadian rhythm effects or meal-timing interactions, but less effective for maintaining consistent anabolic signaling across a 24-hour period.
- Our experience with metabolic research models shows this distinction matters most in studies requiring stable IGF-1 levels. MK-677 produces IGF-1 elevations of 60–80% above baseline maintained across the dosing interval, while GHRP protocols require multiple daily injections to approach similar area-under-curve exposure. The MK-677 formulation we supply uses micronized powder with verified 99.2% purity, ensuring consistent receptor binding across repeated dosing cycles.